Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulat...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2004
|
| _version_ | 1797052197631950848 |
|---|---|
| author | Parissis, J Adamopoulos, S Antoniades, C Kostakis, G Rigas, A Kyrzopoulos, S Iliodromitis, E Kremastinos, D |
| author_facet | Parissis, J Adamopoulos, S Antoniades, C Kostakis, G Rigas, A Kyrzopoulos, S Iliodromitis, E Kremastinos, D |
| author_sort | Parissis, J |
| collection | OXFORD |
| description | This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients. |
| first_indexed | 2024-03-06T18:29:05Z |
| format | Journal article |
| id | oxford-uuid:0900f39e-a490-43e6-a0d3-2a78b128230d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:29:05Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:0900f39e-a490-43e6-a0d3-2a78b128230d2022-03-26T09:15:56ZEffects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0900f39e-a490-43e6-a0d3-2a78b128230dEnglishSymplectic Elements at Oxford2004Parissis, JAdamopoulos, SAntoniades, CKostakis, GRigas, AKyrzopoulos, SIliodromitis, EKremastinos, DThis randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients. |
| spellingShingle | Parissis, J Adamopoulos, S Antoniades, C Kostakis, G Rigas, A Kyrzopoulos, S Iliodromitis, E Kremastinos, D Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. |
| title | Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. |
| title_full | Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. |
| title_fullStr | Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. |
| title_full_unstemmed | Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. |
| title_short | Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. |
| title_sort | effects of levosimendan on circulating pro inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure |
| work_keys_str_mv | AT parissisj effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT adamopouloss effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT antoniadesc effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT kostakisg effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT rigasa effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT kyrzopouloss effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT iliodromitise effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure AT kremastinosd effectsoflevosimendanoncirculatingproinflammatorycytokinesandsolubleapoptosismediatorsinpatientswithdecompensatedadvancedheartfailure |